BR9704879A - Composição de vacina e uso de um vírus cav vivo - Google Patents

Composição de vacina e uso de um vírus cav vivo

Info

Publication number
BR9704879A
BR9704879A BR9704879A BR9704879A BR9704879A BR 9704879 A BR9704879 A BR 9704879A BR 9704879 A BR9704879 A BR 9704879A BR 9704879 A BR9704879 A BR 9704879A BR 9704879 A BR9704879 A BR 9704879A
Authority
BR
Brazil
Prior art keywords
vaccine composition
inactivated
live cav
vaccines
cav virus
Prior art date
Application number
BR9704879A
Other languages
English (en)
Inventor
Carla Christina Schrier
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of BR9704879A publication Critical patent/BR9704879A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/816—Viral vaccine for avian species, e.g. poultry or other birds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
BR9704879A 1996-09-27 1997-09-26 Composição de vacina e uso de um vírus cav vivo BR9704879A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96202708 1996-09-27

Publications (1)

Publication Number Publication Date
BR9704879A true BR9704879A (pt) 1998-10-27

Family

ID=8224440

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9704879A BR9704879A (pt) 1996-09-27 1997-09-26 Composição de vacina e uso de um vírus cav vivo

Country Status (14)

Country Link
US (1) US5914113A (pt)
EP (1) EP0838222B1 (pt)
JP (1) JP4108796B2 (pt)
KR (1) KR100447297B1 (pt)
AT (1) ATE274355T1 (pt)
AU (1) AU715947B2 (pt)
BR (1) BR9704879A (pt)
CA (1) CA2216410C (pt)
DE (1) DE69730393T2 (pt)
DK (1) DK0838222T3 (pt)
ES (1) ES2227651T3 (pt)
HU (1) HU223734B1 (pt)
PT (1) PT838222E (pt)
ZA (1) ZA978434B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1140152T3 (da) 1998-12-21 2003-12-01 Akzo Nobel Nv Fremgangsmåde til fremstilling af inaktiverede v/o-emulsion-adjuvans-vacciner
US7026155B2 (en) 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
JP2001275664A (ja) 2000-02-29 2001-10-09 Akzo Nobel Nv 低い病原性のニワトリ貧血ウイルス
US6593134B1 (en) * 2000-03-10 2003-07-15 Cornell Research Foundation, Inc. Method of propagating chicken infectious anemia virus
US20040208842A1 (en) * 2001-09-18 2004-10-21 Ritchie Branson W. Antimicrobial cleansing compositions and methods of use
US20040151765A1 (en) * 2001-09-18 2004-08-05 Ritchie Branson W. Methods and compositions for wound management
US20070003508A1 (en) 2005-07-01 2007-01-04 Wooley Richard E Methods and compositions for promoting wound healing
US6861410B1 (en) * 2002-03-21 2005-03-01 Chiron Corporation Immunological adjuvant compositions
US7217420B2 (en) * 2002-07-13 2007-05-15 The University Of Georgia Research Foundation, Inc. Mycoplasma gallisepticum formulation
US20070185202A1 (en) * 2004-03-03 2007-08-09 University Of Georgia Research Foundation, Inc. Methods and compositions for ophthalmic treatment of fungal and bacterial infections
BR112012012921A2 (pt) * 2009-12-01 2016-10-25 Intervet Int Bv uso de uma quantidade imunogênica de um vírus da doença de newcastle inativado e um adjuvante, composição farmacêutica, e, kit de partes
CA2725435C (en) 2009-12-15 2023-01-03 University Of Saskatchewan Vaccines for inclusion body hepatitis
KR20200039025A (ko) * 2013-09-19 2020-04-14 조에티스 서비시즈 엘엘씨 유성 아쥬반트
KR20180129926A (ko) * 2016-06-02 2018-12-05 조에티스 서비시즈 엘엘씨 감염성 기관지염에 대한 백신
CN107603958A (zh) * 2017-09-29 2018-01-19 天津农学院 融合表达TM‑1基因和gD基因重组腺病毒的构建方法及重组腺病毒和应用
CN110433288A (zh) * 2018-05-03 2019-11-12 乐斯福公司 试剂盒和β-葡聚糖提取物在禽类动物免疫增强中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2170708A (en) * 1937-04-29 1939-08-22 Atlas Tack Corp Eyelet
FR2801M (fr) * 1963-05-20 1964-09-21 Pierre Lepine Vaccins dits interférentiels contre les maladies a virus.
IL74289A (en) * 1985-02-10 1989-02-28 Israel State Vaccine system comprising a live-non-virulent vaccine and an adjuvant
US5037650A (en) * 1988-03-08 1991-08-06 Akzo N.V. Live combination vaccine
FR2667245B1 (fr) * 1990-10-01 1992-11-06 Rhone Merieux Association vaccinale contre les pathogenes infectieux.
US5686077A (en) * 1991-09-20 1997-11-11 Akzo Nobel N.V. Methods of immunization of poultry with vaccines against chicken anemia agent (CAA)
ZA927014B (en) * 1991-09-20 1993-03-19 Akzo Nv Chicken anaemia agent vaccine.
CA2181862C (en) * 1995-08-01 2009-12-22 Carla Christina Schrier Mild newcastle disease virus vaccine
EP0770397B1 (en) * 1995-10-18 2004-04-21 Akzo Nobel N.V. Newcastle disease virus combination vaccine
FR2751225B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire

Also Published As

Publication number Publication date
KR100447297B1 (ko) 2004-11-06
JPH10114678A (ja) 1998-05-06
CA2216410A1 (en) 1998-03-27
DE69730393D1 (de) 2004-09-30
KR19980025002A (ko) 1998-07-06
HU223734B1 (hu) 2004-12-28
DK0838222T3 (da) 2004-12-13
JP4108796B2 (ja) 2008-06-25
HUP9701586A2 (hu) 1998-07-28
HUP9701586A3 (en) 2001-06-28
CA2216410C (en) 2007-04-17
MX9707402A (es) 1998-06-30
DE69730393T2 (de) 2005-09-01
ZA978434B (en) 1998-03-26
ATE274355T1 (de) 2004-09-15
ES2227651T3 (es) 2005-04-01
US5914113A (en) 1999-06-22
EP0838222B1 (en) 2004-08-25
EP0838222A1 (en) 1998-04-29
AU3926097A (en) 1998-04-02
AU715947B2 (en) 2000-02-10
PT838222E (pt) 2004-11-30
HU9701586D0 (en) 1997-11-28

Similar Documents

Publication Publication Date Title
DE69632235D1 (de) Newcastle-Krankheitsvirus-Kombinationsimpfstoff
NO20001768L (no) Viruskapsomervaksine, fremgangsmÕte til fremstilling samt anvendelse derav
DK0838222T3 (da) Vaccinesammensætninger, der omfatter inaktiverede immunogener og levende kyllingeanæmi-virus (CAV)
DE69016956D1 (de) Rekombinantes Truthahn-Herpesvirus und davon abgeleiteter Lebendimpfstoffvektor.
BRPI9911870B8 (pt) vacina de parvovírus e circovírus de suíno
DE60012042D1 (de) Entepneumovirus und entsprechendes impfstoff
FI913476A7 (fi) Konjugaattirokotteita, jotka sisältävät immunogeenista proteiinia, HIV-tyyppisiä peptidejä ja anionisia ryhmiä
CY1105010T1 (el) Πεπτιδια που λαμβανονται απο τη συνδεση (g) πρωτεϊνης του αναπνευστικου συνκυτιακου ιου
ATE377428T1 (de) Rotavirus-impfstoff
DE69531793D1 (de) Immunogene zubereitungen
HUP0101652A1 (hu) Új kompozíció
DE68920345D1 (de) Lebendes Kombinationsvakzin.
PT729509E (pt) Vacina contra papeira contendo uma estirpe do virus jerryl-lynn
MX9301736A (es) Vacuna de bacterina-toxoide de pasteurella haemolytica tipo a-1.
WO2002024147A3 (en) Avian pneumovirus vaccine
GB9303681D0 (en) Vaccines
HU0100908D0 (en) Chicken anaemia viruses of low pathogenicity
FR2698271B1 (fr) Vaccin contre le virus de la leucémie bovine, nouveau peptide immunogène et kit de vaccination.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/04/2008, OBSERVADAS AS CONDICOES LEGAIS.

B24C Patent annual fee: request for for restoration

Free format text: REFERENTE A 15A ANUIDADE(S), CONFORME ART. 87 DA LPI 9.279.

B24H Lapse because of non-payment of annual fees (definitively: art 78 iv lpi)
B24F Patent annual fee: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 24.8 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2606 DE 15-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.